An attenuated CMV vaccine with a deletion in tegument protein GP83 (pp65 homolog) protects against placental infection and improves pregnancy outcome in a Guinea pig challenge model

Future Virology

Volumn 8, Issue 12, 2013, Pages 1151-1160

  Schleiss, Mark R ^a   Buus, Ryan J ^a,b   Choi, K Yeon ^a,c   Mcgregor, Alistair ^a,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

CMV immune evasion; CMV pp65; CMV UL83; CMV vaccine; cytomegalovirus; GPCMV GP83; Guinea pig challenge model; Guinea pig CMV; live, attenuated CMV vaccine; vaccine efficacy

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; CYTOMEGALOVIRUS VACCINE; PLACEBO; UNCLASSIFIED DRUG; VAM409 VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONGENITAL INFECTION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GUINEA PIG; IMMUNE RESPONSE; IN SITU HYBRIDIZATION; INFECTION; MALE; MORTALITY; NONHUMAN; PLACENTAL INFECTION; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROVOCATION TEST; SECOND TRIMESTER PREGNANCY; VACCINATION; VIRUS LOAD;

EID: 84889570107     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.13.107     Document Type: Article

References (41)

1. Whitley RJ. Congenital cytomegalovirus infection: Epidemiology and treatment. Adv. Exp. Med. Biol. 549, 155-160 (2004 (Pubitemid 38968192)
2. Williamson WD, Demmler GJ, Percy AK, Catlin FI. Progressive hearing loss in infants with asymptomatic congenital cytomegalovirus infection. Pediatrics 90(6), 862-866 (1992
3. Cheeran MC, Lokensgard JR, Schleiss MR. Neuropathogenesis of congenital cytomegalovirus infection: Disease mechanisms and prospects for intervention. Clin. Microbiol. Rev. 22(1), 99-126 (2009
4. Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R. Vaccine development to prevent cytomegalovirus disease: Report from the National Vaccine Advisory Committee. Clin. Infect. Dis. 39(2), 233-239 (2004 (Pubitemid 38971495)
5. Pass RF, Zhang C, Evans A et al. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med. 360(12), 1191-1199 (2009
6. Griffiths PD, Stanton A, McCarrell E et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A Phase 2 randomised placebocontrolled trial. Lancet 377(9773), 1256-1263 (2011
7. Sabbaj S, Pass RF, Goepfert PA, Pichon S. Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. J. Infect. Dis. 203(11), 1534-1541 (2011
8. Sung H, Schleiss MR. Update on the current status of cytomegalovirus vaccines. Expert Rev. Vaccines 9(11), 1303-1314 (2010
9. Heineman TC, Schleiss M, Bernstein DI et al. A Phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J. Infect. Dis. 193(10), 1350-1360 (2006 (Pubitemid 43673381)
10. Krause PR, Bialek SR, Boppana SB et al. Priorities for CMV vaccine development. Vaccine doi:10.1016/j.vaccine.2013.09.042 (2013) (Epub ahead of print
11. Bia FJ, Miller SA, Davidson KH. The Guinea pig cytomegalovirus model of congenital human cytomegalovirus infection. Birth Defects Orig. Artic. Ser. 20(1), 233-241 (1984 (Pubitemid 15224984)
12. Schleiss MR. Nonprimate models of congenital cytomegalovirus (CMV) infection: Gaining insight into pathogenesis and prevention of disease in newborns. ILAR J. 47(1), 65-72 (2006 (Pubitemid 43013513)
13. Schleiss MR, Bourne N, Bernstein DI. Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the Guinea pig model of congenital CMV infection. J. Infect. Dis. 188(12), 1868-1874 (2003 (Pubitemid 38064872)
14. Schleiss MR, Bourne N, Stroup G, Bravo FJ, Jensen NJ, Bernstein DI. Protection against congenital cytomegalovirus infection and disease in Guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J. Infect. Dis. 189(8), 1374-1381 (2004 (Pubitemid 38543585)
15. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333(16), 1038-1044 (1995
16. Schleiss MR, Lacayo JC, Belkaid Y et al. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the Guinea pig model of congenital cytomegalovirus infection. J. Infect. Dis. 195(6), 789-798 (2007 (Pubitemid 46363923)
17. Browne EP, Wing B, Coleman D, Shenk T. Altered cellular mRNA levels in human cytomegalovirus-infected fibroblasts: Viral block to the accumulation of antiviral mRNAs. J. Virol. 75(24), 12319-12330 (2001 (Pubitemid 33115904)
18. Abate DA, Watanabe S, Mocarski ES. Major human cytomegalovirus structural protein pp65 (ppUL83) prevents interferon response factor 3 activation in the interferon response. J. Virol. 78(20), 10995-11006 (2004 (Pubitemid 39299640)
19. Schleiss MR, Mcgregor A, Jensen NJ, Erdem G, Aktan L Molecular characterization of the Guinea pig cytomegalovirus UL83 (pp65 protein homolog. Virus Genes 19(3), 205-221 (1999 (Pubitemid 29535175)
20. McGregor A, Liu F, Schleiss MR Molecular, biological, and in vivo characterization of the Guinea pig cytomegalovirus (CMV homologs of the human CMV matrix proteins pp71 (UL82) and pp65 (UL83). J. Virol. 78(18), 9872-9889 (2004 (Pubitemid 39187107)
21. Wills MR, Carmichael AJ, Mynard K et al The human cytotoxic T-lymphocyte (CTL response to cytomegalovirus is dominated by structural protein pp65: Frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J. Virol. 70(11), 7569-7579 (1996 (Pubitemid 26340108)
22. Mcgregor A, Liu F, Schleiss MR Molecular, biological, and in vivo characterization of the Guinea pig cytomegalovirus (CMV homologs of the human CMV matrix proteins pp71 (UL82) and pp65 (UL83). J. Virol. 78(18), 9872-9889 (2004 (Pubitemid 39187107)
23. Schleiss MR. Cloning and characterization of the Guinea pig cytomegalovirus glycoprotein B gene. Virology 202(1), 173-185 (1994 (Pubitemid 24241989)
24. Griffith BP, Chen M, Isom HC. Role of primary and secondary maternal viremia in transplacental Guinea pig cytomegalovirus transfer. J. Virol. 64(5), 1991-1997 (1990 (Pubitemid 20148440)
25. Griffith BP, Aquino-De Jesus MJ. Guinea pig model of congenital cytomegalovirus infection. Transplant Proc. 23(3 Suppl. 3), 29-31; discussion 31 (1991
26. Schleiss MR, Choi KY, Anderson J et al. Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female Guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model. Vaccine doi:10.1016/j.vaccine.2013. .10 (2013) (Epub ahead of print
27. Leviton MP, Lacayo JC, Choi KY, Hernandez-Alvarado N, Wey A, Schleiss MR. An attenuated cytomegalovirus vaccine with a deletion of a viral chemokine gene is protective against congenital CMV transmission in a Guinea pig model. Clin. Dev. Immunol. 2013, 906948 (2013
28. Bia FJ, Griffith BP, Tarsio M, Hsiung GD. Vaccination for the prevention of maternal and fetal infection with Guinea pig cytomegalovirus. J. Infect. Dis. 142(5), 732-738 (1980 (Pubitemid 11138427)
29. Cicin-Sain L, Bubic I, Schnee M et al. Targeted deletion of regions rich in immuneevasive genes from the cytomegalovirus genome as a novel vaccine strategy. J. Virol. 81(24), 13825-13834 (2007 (Pubitemid 350247876)
30. Mohr CA, Cicin-Sain L, Wagner M et al. Engineering of cytomegalovirus genomes for recombinant live herpesvirus vaccines. Int. J. Med. Microbiol. 298(1-2), 115-125 (2008 (Pubitemid 350216552)
31. Crumpler MM, Choi KY, Mcvoy MA, Schleiss MR. A live Guinea pig cytomegalovirus vaccine deleted of three putative immune evasion genes is highly attenuated but remains immunogenic in a vaccine/challenge model of congenital cytomegalovirus infection. Vaccine 27(31), 4209-4218 (2009
32. Soderberg-Naucler C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J. Intern. Med. 259(3), 219-246 (2006
33. Schleiss MR, Lacayo JC, Belkaid Y et al. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the Guinea pig model of congenital cytomegalovirus infection. J. Infect. Dis. 195(6), 789-798 (2007 (Pubitemid 46363923)
34. Browne EP, Shenk T. Human cytomegalovirus UL83-coded pp65 virion protein inhibits antiviral gene expression in infected cells. Proc. Natl Acad. Sci. USA 100(20), 11439-11444 (2003 (Pubitemid 37205954)
35. Abate DA, Watanabe S, Mocarski ES. Major human cytomegalovirus structural protein pp65 (ppUL83) prevents interferon response factor 3 activation in the interferon response. J. Virol. 78(20), 10995-11006 (2004 (Pubitemid 39299640)
36. Griffith BP, McCormick SR, Fong CK, Lavallee JT, Lucia HL, Goff E. The placenta as a site of cytomegalovirus infection in Guinea pigs. J. Virol. 55(2), 402-409 (1985 (Pubitemid 16239728)
37. Griffith BP, Isom HC, Lavallee JT. Cellular localization of cytomegalovirus nucleic acids in Guinea pig salivary glands by in situ hybridization. J. Virol. Methods 27(2), 145-157 (1990
38. Hashimoto K, Yamada S, Katano H et al. Effects of immunization of pregnant Guinea pigs with Guinea pig cytomegalovirus glycoprotein B on viral spread in the placenta. Vaccine 31(31), 3199-3205 (2013
39. Nozawa N, Yamamoto Y, Fukui Y et al. Identification of a 1.6 kb genome locus of Guinea pig cytomegalovirus required for efficient viral growth in animals but not in cell culture. Virology 379(1), 45-54 (2008
40. Yamada S, Nozawa N, Katano H et al. Characterization of the Guinea pig cytomegalovirus genome locus that encodes homologs of human cytomegalovirus major immediate-early genes, UL128, and UL130. Virology 391(1), 99-106 (2009
41. Auerbach M, Yan D, Fouts A et al. Characterization of the Guinea pig CMV gH/ gL/GP129/GP131/GP133 complex in infection and spread. Virology 441(1), 75-84 (2013)